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Abstract
Background: Peritoneal dialysis (PD) is the preferred dialysis modality in children. Its major
drawback is the limited technique survival due to infections and progressive ultrafiltration failure.
Conventional PD solutions exert marked acute and chronic toxicity to local tissues. Prolonged
exposure is associated with severe histopathological alterations including vasculopathy,
neoangiogenesis, submesothelial fibrosis and a gradual loss of the mesothelial cell layer. Recently,
more biocompatible PD solutions containing reduced amounts of toxic glucose degradation
products (GDPs) and buffered at neutral pH have been introduced into clinical practice. These
solutions contain lactate, bicarbonate or a combination of both as buffer substance. Increasing
evidence from clinical trials in adults and children suggests that the new PD fluids may allow for
better long-term preservation of peritoneal morphology and function. However, the relative
importance of the buffer in neutral-pH, low-GDP fluids is still unclear. In vitro, lactate is cytotoxic
and vasoactive at the concentrations used in PD fluids. The BIOKID trial is designed to clarify the
clinical significance of the buffer choice in biocompatible PD fluids.
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BMC Nephrology 2004, 5:14 http://www.biomedcentral.com/1471-2369/5/14Methods/design: The objective of the study is to test the hypothesis that bicarbonate based PD
solutions may allow for a better preservation of peritoneal transport characteristics in children
than solutions containing lactate buffer. Secondary objectives are to assess any impact of the buffer
system on acid-base status, peritoneal tissue integrity and the incidence and severity of peritonitis.
After a run-in period of 2 months during which a targeted cohort of 60 patients is treated with a 
conventional, lactate buffered, acidic, GDP containing PD fluid, patients will be stratified according 
to residual renal function and type of phosphate binding medication and randomized to receive 
either the lactate-containing Balance solution or the bicarbonate-buffered Bicavera® solution for a 
period of 10 months. Patients will be monitored by monthly physical and laboratory examinations. 
Peritoneal equilibration tests, 24-h dialysate and urine collections will be performed 4 times. 
Peritoneal biopsies will be obtained on occasion of intraabdominal surgery. Changes in small solute 
transport rates, markers of peritoneal tissue turnover in the effluent, acid-base status and 
peritonitis rates and severity will be analyzed.
Background
Peritoneal dialysis (PD) is the preferred dialysis modality
in children. Advantages of PD over hemodialysis relevant
to pediatric patients include its compatibility with a nor-
mal lifestyle and full psychosocial integration, the contin-
uous mode of blood purification without dysequilibrium
conditions, the absence of vascular access issues and the
avoidance of puncture pain. However, the major draw-
back of PD is its limited technique survival. Almost fifty
percent of adult as well as pediatric PD patients must
switch to hemodialysis within 4 to 5 years of treatment
[1,2]. While the incidence of PD failure due to infectious
complications is steadily decreasing, loss of ultrafiltration
due to degenerative changes of the peritoneal tissue is
becoming the leading cause of non-elective termination
of PD [1]. Histopathological alterations induced by expo-
sure to PD solutions include a severe vasculopathy,
neoangiogenesis, submesothelial fibrosis and a progres-
sive loss of the mesothelial cell layer [3-5]. Acute and
chronic toxicity of standard PD fluids to mesothelial cells,
affecting cell turnover and the pattern of growth factor
and cytokine release, is considered a key mechanism
underlying the progressive transformation of the perito-
neum. Conventional PD fluids contain large doses of glu-
cose, are lactate-buffered at acidic pH and contaminated
with toxic glucose degradation products (GDP) formed
during heat sterilization. Low pH, lactate and hyperosmo-
lar glucose independently impair mesothelial cell func-
tions [6-9]. GDPs impair the viability and functional
integrity of mesothelial cells upon extended exposure
[10], and stimulate VEGF and TGF-β release by mesothe-
lial cells [11,12].
In recent years, a new generation of more biocompatible
PD fluids has been introduced into clinical practice. The
separation of alkaline and acidic fluid compartments in
pluri-chamber bags permits to sterilize glucose at very low
pH with greatly reduced GDP formation and yet produce
pH-neutral final dialysis solutions, using lactate and/or
bicarbonate as a buffer. We recently compared the safety
and efficacy of Bicavera® (Fresenius), a purely bicarbonate-
buffered biocompatible PD solution, with that of a con-
ventional acidic, lactate buffered solution by a three-
month crossover trial in children on automated PD [13].
We observed a marked increase of the mesothelial cell
marker CA125 in the effluent during Bicavera® treatment,
which was readily reversible when patients returned to
conventional solution. This effect was also observed with
lactate- or lactate/bicarbonate-buffered biocompatible PD
solutions [14,15], and is interpreted as a functional and/
or numeric recovery of mesothelial cells exposed to these
fluids. Moreover, in agreement with previous studies
[7,16] we observed a trend towards increasing small sol-
ute permeability with the standard solution; this trend
was absent when Bicavera® was used. Two studies
observed a slightly lower initial increase of the functional
peritoneal surface area during a single PD dwell with pH-
neutral compared to acidic solutions compatible with
reduced peritoneal capillary recruitment; this trend was
significant in one study [17-19]. Fischbach et al. also dem-
onstrated lower intraperitoneal pressure and less inflow
pain in children receiving a low-GDP, neutral-pH PD
solution [19]. Finally, we noted a more effective compen-
sation of metabolic acidosis with Bicavera® than with lac-
tate buffered conventional fluid despite identical content
of base equivalents.
While these results are encouraging with respect to the
long term preservation of the peritoneal membrane and
strongly favour the primary use of low-GDP, neutral-pH
biocompatible PD fluids, the relative importance of the
buffer system is still unclear. In vitro data suggest that lac-
tate per se may compromise local cell functions independ-
ently of pH by affecting the cellular redox state and
reducing cellular energy sources [6,20-22]. By intravital
microcopy of rat peritoneum, lactate-based neutral-pH
PD solution caused mesenteric vasodilation whereas
bicarbonate buffered PD fluid had no hemodynamicPage 2 of 6
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tional and biocompatible PD fluids were unsuitable by
design to identify any role of the buffer for peritoneal tis-
sue integrity, perfusion and the acute or chronic regula-
tion of peritoneal solute transport, since the solutions
tested differed not only by the buffer used, but also by pH
and GDP content. To clarify the role of the buffer the
BIOKID trial has been designed. Patients participating in
this trial will be exposed to two solutions which are both
pH neutral and of low GDP content, but contain either
pure bicarbonate or pure lactate as buffer compound.
Methods/design
Objectives of the study
The European Pediatric Peritoneal Dialysis Study Group
(EPPS) plans a prospective, randomized study with
administration of pH neutral, low-GDP PD solutions con-
taining either lactate or bicarbonate buffer over a period
of 10 months.
The primary objective is to evaluate the effect of lactate vs.
bicarbonate buffer on peritoneal transport capacity in
children. The hypothesis to be tested is that bicarbonate
based PD solutions may allow for a significantly better
preservation of peritoneal transport characteristics (D/
PCrea) in children compared to a solution containing lac-
tate buffer. Secondary objectives will be to assess differen-
tial effects of lactate and bicarbonate buffered PD fluids
on acid-base status, surrogate parameters of peritoneal
biocompatibility and local and systemic carbonyl stress,
peritoneal morphology, the incidence and severity of peri-
tonitis, statural growth and nutritional status. Moreover,
this study will be used to assess genetic determinants of
the peritoneal transporter status and the evolution of peri-
toneal morphology over time.
Study design
This is a multicenter open-labelled, controlled, rand-
omized clinical trial, designed to test the effects of the
buffer substance in biocompatible PD fluids on peritoneal
small solute transport capacity. All subjects will undergo a
2-month run-in period, in which they receive conven-
tional lactate buffered, acidic, GDP containing PD fluid.
During this period, patient eligibility for the trial will be
verified and the dialysis dose will be optimized if neces-
sary to ensure appropriate PD adequacy. At the end of this
period, the patients will be stratified according to residual
renal function (greater or less than 100 ml urine output/
day/1.73 m2) and the type of phosphate binder therapy
(Sevelamer vs. calcium-containing phosphate binders),
since these variables may affect the overall efficacy of met-
abolic acidosis control. Following stratification, subjects
will be randomized centrally to receive either the lactate-
containing Balance solution or the bicarbonate buffered
Bicavera® solution for a period of 10 months. Both during
the run-in period and during the intervention phase,
patients will be monitored by monthly clinical and labo-
ratory examinations, including capillary blood gas analy-
ses. In addition, peritoneal equilibration tests (PETs), 24-
hour dialysate and urine collections and intraabdominal
pressure assessments will be performed at time of rand-
omization (with conventional PD fluid) and after 3, 6 and
10 months of treatment (with the study solutions). Also,
peritoneal biopsies will be performed on occasion of
intraabdominal sugery or laparoscopy prior to start and
after termination of the study (usually at time of catheter
insertion and renal transplantation).
Primary outcome measure
The primary outcome measure will be the longitudinal
change in 4h-D/Pcreatinine in the sequential PET examina-
tions. Differential changes in this parameter will indicate
differences in the development of the peritoneal solute
transport status over time.
Secondary outcome measures
Secondary outcome measures will be surrogate parame-
ters of mesothelial cell viability (CA-125), peritoneal
neoangiogenesis (VEGF), fibrotic activity (TGF-β) and
local inflammation (IL-6). With the same intention, the
evolution of peritoneal histomorphology will be assessed
in all patients available for sequential biopsies. Moreover,
possible differential effects of lactate and bicarbonate
buffer on the control of metabolic acidosis will be
assessed by monthly blood gas analyses. Finally, the inci-
dence and clinical course of peritonitis will be recorded as
a possible indirect marker of local peritoneal macrophage
function.
Inclusion criteria
Criteria for inclusion in the study are 1) patients above 1
month and less than 19 years of age, 2) end-stage renal
disease with manual or automated continuous peritoneal
dialysis as maintenance treatment modality, 3) a fill vol-
ume approximately of 1100 ml/1.73 m2 body surface
area, 4) the most recent episode of PD-associated perito-
nitis, if any, occurred more than 3 weeks ago, 5) signed
informed consent by parent/guardian, with a subject aged
> 7 years also signing an age-appropriate assent form.
Exclusion criteria
Criteria for exclusion from the study are 1) reduced effi-
ciency of peritoneal dialysis due to anatomic anomalies or
intraperitoneal adhesions, 2) uncontrolled hyperphos-
phatemia, 3) severe pulmonary, cardiac, hepatic or sys-
temic disease including any kind of malignancy, and 4)
current or recent (within 30 days) exposure to any inves-
tigational drug.Page 3 of 6
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Reasons for permanently discontinuing the study medica-
tion are 1) renal transplantation, 2) switch to hemodialy-
sis due to PD technique failure, 3) patient/parent
withdrawal of consent of participate, 4) patient moving
out of the area to a location with no participating center
within reasonable distance, and 5) a severe adverse event.
Study medications
The composition of the study fluids is given in Table 1.
Both Bicavera® and Balance will be available in three dif-
ferent glucose concentrations to meet individual ultrafil-
tration requirements. The fluids will be administered at a
dose of approximately 1,100 ml/m2 body surface area per
dwell. Both in patients on CAPD and CCPD, the number
of cycles and dwell times can be varied according to clini-
cal needs. The dose of dialysis will be tailored individually
in order to ascertain a minimum total weekly Kt/VUrea of ≥
2.0.
Any kind of concomitant medication during the run-in
period and the study period will be documented in the
case report form with respect to type, dosage and mode of
delivery. In case of peritonitis (defined by cloudy effluent,
white blood cell count greater than 100/mm3 with more
than 50% polymorphonuclear leukocytes), treatment will
be given intraperitoneally according to international pedi-
atric guidelines [24] using cefazoline and ceftazidime in
patients with mild peritonitis and a glycopeptide/ceftazi-
dime combination in patients with defined risk factors for
severe course and poor outcome.
Bicarbonate supplementation will be discontinued at start
of the run-in period and only re-instituted if blood bicar-
bonate levels drop below 17 mmol/l despite sufficient
dialysis efficacy. The recommended dosage is 0.5 mmol/
kg/day divided into 3 doses.
Clinical safety monitoring
An adverse event is defined as any untoward medical
occurence in a patient who takes the study medication. It
does not necessarily have a causal relationship with this
treatment. This may be an unfavourable and unintended
sign, symptom or disease, which is observed after expo-
sure to the study medication, whether or not considered
related to the treatment. Moreover, the participating
investigators will report all treatment-emergent adverse
events that are observed on the online adverse event form.
This applies regardless of the clinical significance or the
assessment of study drug causality. In this trial, such
adverse events may include inflow pain, severe changes of
the state of hydration, abnormal electrolyte and glucose
blood levels, peritonitis, abdominal hernia, and allergic
reactions.
A severe adverse event or reaction is any untoward medi-
cal occurrence that a) results in death, b) is life-threaten-
ing, c) requires inpatient hospitalization or prolonges an
existing hospitalization, or d) results in persistent or sig-
nificant disability/incapacity.
Any serious adverse event, whether or not considered
related to the study medication, and any unexpected drug
reactions with significant hazard to the patient popula-
tion will be reported to the responsible safety assessor at
Fresenius Medical Care by phone or by fax within 24
hours following first knowledge of the event. Alternatively
the clinical monitor may be informed. This information
will be forwarded to and evaluated by the safety monitor-
ing committee, and reports of serious adverse reactions
will be disseminated to all participating centers for sub-
mission to their respective institutional review boards.
Fresenius Medical Care is responsible for passing on the
information to relevant supervisory authorities.
Data management
Data acquisition will be entirely through the internet. The
case report form menus will be used to record the follow-
Table 1: 
Balance 1.5% Balance 2.3% Balance 4.25% Bicavera® 1.5% Bicavera® 2.3% Bicavera® 4.25%
Sodium (mmol/l) 134 134 134 134 134 134
Calcium (mmol/l) 1.75 1.75 1.75 1.75 1.75 1.75
Magnesium (mmol/l) 0.5 0.5 0.5 0.5 0.5 0.5
Chloride (mmol/l) 101.5 101.5 101.5 104.5 104.5 104.5
L-Lactate (mmol/l) 35 35 35 - - -
Bicarbonate (mmol/l) - - - 34 34 34
Glucose-monohydrate (g/l) 15 23 42.5 15 23 42.5
Osmolarity (mosmol/l) 358 401 511 358 399 509
PH 7.4 7.4 7.4 7.4 7.4 7.4Page 4 of 6
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and biochemical examination variables, 3) study and con-
current medications, and 4) adverse events.
Periodic computerized audit reports will be run to moni-
tor data quality and completeness. The data base is stored
on a server drive that is backed up to tape daily by Tel-A-
Vision, Media Networking GmbH.
In order to insure confidentiality, data from each patient
will be recorded in the computer data base with a unique
contributing center code, study code, sequence number
and patient initials. Patient names are never entered
online or forwarded in any other form to the coordinating
office.
Sample size estimation
The primary study outcome is the change in 4h-D/PCr
from the time of randomization to the conclusion of the
10-month study period. In a previous trial we demon-
strated a 6% increase of D/PCr in children on lactate-buff-
ered PD fluid in contrast to a 4% decrease in D/PCr using
bicarbonate buffered fluid within 3 months of exposure,
resulting in a statistically significant 10% difference in the
evolution of peritoneal creatinine transport rate [13].
Assuming that this effect was at least in part due to the dif-
ferent buffer substances applied, a difference in D/PCr at
least 7 ± 10% can be expected when Balance and Bicavera®
are applied for 10 months. To detect this difference with a
sensitivity of 80% and an error probability of 5%, at least
15 patients per randomization group will be required.
Assuming a 50% drop-out rate due to renal transplanta-
tion and other reasons in the course of the study, 60
patients will have to be enrolled.
Statistical approach
A computer based randomization protocol will be gener-
ated and applied centrally at the end of the run-in period.
Baseline comparability between the two treatment groups
will be evaluated with respect to entry criteria. Chi-square
and t-tests will be used to assess differences between the
two groups on the baseline variables. Any variables that
are found to be discrepant between the two groups and
that are related to the outcome variables will be treated as
co-variates in later analyses.
In order to evaluate the patients' change in D/PCr ratios,
two strategies will be employed:
1. Repeated measure ANOVA will be performed on those
patients who complete the 10-month observation period
on the study medications.
2. The Kaplan-Meier method will be used to estimate the
time in which patients are likely to display a ≥ 7.5 %
increase in the D/PCrea ratio during the 10-month period.
All patients started on study medication will be available
for this analytical approach.
The same strategies will be used to analyze secondary out-
come variables.
Publication of study results
All publications will be authored by members of the sci-
entific advisory committee. Co-authors will have contrib-
uted to the design, analysis, execution and actual
reporting of the study.
Study investigators
Steering committee: C.P. Schmitt, F. Schaefer, K.E. Bonzel,
K. Rönnholm
Scientific advisory committee: M. Almeida, K. Arbeiter, G.
Ardissino, K.E. Bonzel, A. Edefonti, M. Fischbach, K. Hal-
uany, J. Misselwitz, Markus J. Kemper, K. Rönnholm, F.
Schaefer, C.P. Schmitt, S. Wygoda
Safety monitoring committee: V. Schwenger, U. Querfeld,
G. Offner
Discussion
We report the protocol of a randomized clinical trial
designed to test the effect of the buffer type on the evolu-
tion of peritoneal tissue integrity and transport function
in children treated with 'biocompatible', i.e. neutral-pH,
low-GDP PD solutions. The study utilizes the availability
of two novel biocompatible PD solutions manufactured
by the same company which differ selectively in the buffer
employed, namely either pure lactate or pure bicarbonate.
The comparative administration of these solutions will
provide information on differences in peritoneal cell via-
bility, tissue morphology, local host defense and solute
transfer capacity potentially inferred by cytotoxic and/or
vasocative effects of lactate administered to the abdomi-
nal cavity in unphysiological concentrations.
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